Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for cardiovascular disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
The use of statins in the primary prevention of cardiovasculardisease: an online tool for shared-decision making 2019 www.kce.fgov.be KCE REPORT 324 THE USE OF STATINS IN THE PRIMARY PREVENTION OF CARDIOVASCULARDISEASE: AN ONLINE TOOL FOR SHARED- DECISION MAKING 2019 www.kce.fgov.be KCE REPORT 324 HEALTH TECHNOLOGY ASSESSMENT THE USE OF STATINS IN THE PRIMARY PREVENTION OF CARDIOVASCULARDISEASE: AN ONLINE TOOL FOR SHARED-DECISION MAKING CHRISTOPHE DE MEESTER (KCE), KARIN RONDIA (KCE), THOMAS (...) GOORDEN (LEF), SABINE JANSSENS (BSM), PIETER STEYAERT (TEMPERA), CHRIS DE LAET (KCE), MICHEL ALBERTIJN (TEMPERA), LAURENCE KOHN (KCE) COLOPHON Title: The use of statins in the primary prevention of cardiovasculardisease: an online tool for shared-decision making Authors: Christophe De Meester (KCE), Karin Rondia (KCE), Thomas Goorden (LEF), Sabine Janssens (BSM), Pieter Steyaert (Tempera), Chris De Laet (KCE), Michel Albertijn (Tempera), Laurence Kohn (KCE) Information specialist: Nicolas Fairon (KCE
disease prevention medications at least 80% of the time. The proportion of patients considered adherent increased by a median of 6.9 percentage points (an increase of ≈ 9.9%) The remaining 21 studies used various tools to measure adherence (e.g., objective provider counts or records, self-report) and reported generally favorable results. CardiovascularDisease Risk Conditions A subset of 17 studies evaluated intervention effects on blood pressure control and lipid control. There was a median increase (...) " or "cardiovasculardiseases").mp. 33. ("cerebrovascular disease" or "cerebrovascular diseases" or "cerebrovascular event" or "cerebrovascular events" or "angina" or "coronary disease" or "coronary artery disease" or "ischemia" or "myocardial ischemic preconditioning").mp. 34. ("transient ischemic attack" or "brain hypoxia ischemia" or "myocardial ischemia" or "heart diseases" or "myocardial infarction" or "stroke" or "cerebrovascular disorders" or "basal ganglia cerebrovascular disease").mp. 35. (angina pectoris
Cardiovasculardisease prevention: applying All Our Health Cardiovasculardisease prevention: applying All Our Health - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Cardiovasculardisease prevention: applying All Our Health Evidence and guidance to help healthcare (...) professionals to prevent heart attacks, strokes and dementia and to improve cardiovascular health. Published 9 January 2019 Last updated 16 December 2019 — From: Documents HTML Details This resource helps: front-line health professionals team leaders or managers senior or strategic leaders to prevent ill health and promote wellbeing as part of their everyday practice. We also recommend important actions that managers and staff holding strategic roles can take. View the full range of topics. Published 9
. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients. Conclusion Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart. Introduction During the past two decades, the outbreak and prevalence of severe acute (...) of coronaviruses. Trends Microbiol 24:490–502 19. Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181–192 20. Chan JW, Ng CK, Chan YH, Mok TY, Lee S, Chu SY, Law WL, Lee MP, Li PC (2003) Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 58:686–689 21. Hu S, Gao R, Liu L, Zhu M, Wang W, Wang Y, Wu Z, Li H, Gu D, Yang Y (2019) Summary of the 2018 report on cardiovasculardiseases
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular risk irrespective of age, but the evidence is less strong for older patients.This prespecified analysis from ODYSSEY OUTCOMES compared the effect of alirocumab vs. placebo in 18 924 patients with recent acute coronary syndrome (ACS) according to age. We examined the effect of assigned (...) treatment on occurrence of the primary study outcome, a composite of coronary heart disease death, myocardial infarction, ischaemic stroke, or unstable angina requiring hospitalization [major adverse cardiovascular event (MACE)] and all-cause death. Relative risk reductions were consistent for patients ≥65 vs. <65 years for MACE [hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.68-0.91 vs. 0.89, 0.80-1.00; Pinteraction = 0.19] and all-cause death [HR 0.77, 0.62-0.95 vs. 0.94, 0.77-1.15
The role of community-based nursing interventions in improving outcomes for individuals with cardiovasculardisease: A systematic review To examine the role of community-based nursing interventions in improving outcomes for community-dwelling individuals with cardiovascular disease.A systematic review and narrative synthesis.Seven electronic databases (MEDLINE, CINAHL, Global Health, LILACS, Africa-Wide Information, IMEMR and WPRIM) were searched from inception to 16 March 2018 without language (...) restrictions.We included studies evaluating the outcomes of interventions led by, or primarily delivered by, nurses for individuals with cardiovasculardisease in community settings. Study selection, data extraction and risk of bias assessments were performed by at least two independent reviewers.Twenty-eight studies met the inclusion criteria and were included in this review. Community-based nursing interventions improved outcomes in four key areas: (1) self-care, (2) health, (3) healthcare utilisation
Comparison of Frequency of Atherosclerotic CardiovascularDisease Events Among Primary and Secondary Prevention Subgroups of the Systolic Blood Pressure Intervention Trial The Pooled Cohort Equation (PCE) predicts 10-year risk of first-time atherosclerotic cardiovasculardisease (ASCVD) events and was incorporated in analyses of a primary and secondary prevention population in the Systolic Blood Pressure Intervention Trial (SPRINT). Whether PCE enhances risk prediction among secondary
A systematic review of community nursing interventions focusing on improving outcomes for individuals exhibiting risk factors of cardiovasculardisease To examine the role of community-based nursing interventions in improving outcomes for community-dwelling individuals exhibiting risk factors of cardiovasculardisease (CVD).A systematic review and narrative synthesis.Seven electronic databases (MEDLINE, CINAHL, Global Health, LILACS, Africa-Wide Information, IMEMR, and WPRIM) were searched from
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovasculardisease: results from the COMPASS trial Adding rivaroxaban to aspirin in patients with stable atherosclerotic disease reduces the recurrence of cardiovasculardisease (CVD) but increases the risk of major bleeding. The aim of this study was to estimate the individual lifetime treatment benefit and harm of adding low-dose rivaroxaban to aspirin in patients with stable (...) cardiovascular disease.Patients with established CVD from the COMPASS trial (n = 27 390) and SMART prospective cohort study (n = 8139) were used. Using the pre-existing lifetime SMART-REACH model for recurrent CVD, and a newly developed Fine and Gray competing risk-adjusted lifetime model for major bleeding, individual treatment effects from adding low-dose rivaroxaban to aspirin in patients with stable CVD were estimated, expressed in terms of (i) life-years free of stroke or myocardial infarction (MI
Mothers of Infants with Heart Defects and Increased Long-Term Risk of CardiovascularDisease "Mothers of Infants with Heart Defects and Increased Long-Term Risk of " by Anne Crowl < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Cardiovasculardisease (CVD) is responsible for approximately 1 in every 3 deaths of women in the United States. Recognizing the symptoms (...) are at an increased risk for CVD. Additional research would determine if the risk further increased in post-menopausal women who are already at a higher risk of developing CVD. Recommended Citation Crowl, Anne, "Mothers of Infants with Heart Defects and Increased Long-Term Risk of CardiovascularDisease" (2019). School of Physician Assistant Studies . 680. https://commons.pacificu.edu/pa/680 DOWNLOADS Since August 02, 2019 Included in Share COinS Browse Search Enter search terms: Select context to search: Authors
Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. To investigate whether fenofibrate as add-on to statin treatment reduce persistent cardiovascular risk in adults with metabolic syndrome in a real world setting.Propensity matched cohort study.Population based cohort in Korea.29 771 adults with metabolic syndrome (≥40 years) receiving statin treatment. 2156 participants receiving combined treatment (statin plus fenofibrate (...) ) were weighted based on propensity score in a 1:5 ratio with 8549 participants using statin only treatment.Primary outcome was composite cardiovascular events including incident coronary heart disease, ischaemic stroke, and death from cardiovascular causes.The incidence rate per 1000 person years of composite cardiovascular events was 17.7 (95% confidence interval 14.4 to 21.8) in the combined treatment group and 22.0 (20.1 to 24.1) in the statin group. The risk of composite cardiovascular events
Medium and long-term risks of specific cardiovasculardiseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. The past few decades have seen substantial improvements in cancer survival, but concerns exist about long-term cardiovasculardisease risk in survivors. Evidence is scarce on the risks of specific cardiovasculardiseases in survivors of a wide range of cancers to inform prevention and management (...) for a range of cardiovasculardisease outcomes using crude and adjusted Cox models. We fitted interactions to investigate effect modification, and flexible parametric survival models to estimate absolute excess risks over time.Between Jan 1, 1990, and Dec 31, 2015, 126 120 individuals with a diagnosis of a cancer of interest still being followed up at least 1 year later were identified and matched to 630 144 controls. After exclusions, 108 215 cancer survivors and 523 541 controls were included
Polypill for CardiovascularDisease Prevention in an Underserved Population. Persons with low socioeconomic status and nonwhite persons in the United States have high rates of cardiovasculardisease. The use of combination pills (also called "polypills") containing low doses of medications with proven benefits for the prevention of cardiovasculardisease may be beneficial in such persons. However, few data are available regarding the use of polypill therapy in underserved communities (...) in the United States, in which adherence to guideline-based care is generally low.We conducted a randomized, controlled trial involving adults without cardiovasculardisease. Participants were assigned to the polypill group or the usual-care group at a federally qualified community health center in Alabama. Components of the polypill were atorvastatin (at a dose of 10 mg), amlodipine (2.5 mg), losartan (25 mg), and hydrochlorothiazide (12.5 mg). The two primary outcomes were the changes from baseline
Modifiable risk factors, cardiovasculardisease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Global estimates of the effect of common modifiable risk factors on cardiovasculardisease and mortality are largely based on data from separate studies, using different methodologies. The Prospective Urban Rural Epidemiology (PURE) study overcomes these limitations by using similar methods to prospectively measure (...) the effect of modifiable risk factors on cardiovasculardisease and mortality across 21 countries (spanning five continents) grouped by different economic levels.In this multinational, prospective cohort study, we examined associations for 14 potentially modifiable risk factors with mortality and cardiovasculardisease in 155 722 participants without a prior history of cardiovasculardisease from 21 high-income, middle-income, or low-income countries (HICs, MICs, or LICs). The primary outcomes
Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of CardiovascularDisease. The relationship between exposure to lower low-density lipoprotein cholesterol (LDL-C) and lower systolic blood pressure (SBP) with the risk of cardiovasculardisease has not been reliably quantified.To assess the association of lifetime exposure to the combination of both lower LDL-C and lower SBP with the lifetime risk (...) of cardiovascular disease.Among 438 952 participants enrolled in the UK Biobank between 2006 and 2010 and followed up through 2018, genetic LDL-C and SBP scores were used as instruments to divide participants into groups with lifetime exposure to lower LDL-C, lower SBP, or both. Differences in plasma LDL-C, SBP, and cardiovascular event rates between the groups were compared to estimate associations with lifetime risk of cardiovascular disease.Differences in plasma LDL-C and SBP compared with participants
plasma glucose ABI Ankle–brachial index ABPM Ambulatory blood pressure monitoring ACCORD Action to Control Cardiovascular Risk in Diabetes ACE Acarbose Cardiovascular Evaluation ACEI Angiotensin-converting enzyme inhibitor ACS Acute coronary syndrome ADA American Diabetes Association ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation ADDITION Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care ADOPT (...) A Diabetes Outcome Progression Trial AF Atrial fibrillation ARB Angiotensin receptor blocker ART Arterial Revascularization Trial ASCEND A Study of Cardiovascular Events iN Diabetes ASCVD Atherosclerotic cardiovasculardisease ATLAS-ACS TIMI 51 Anti-Xa Therapy to Lower cardiovascular events in Addition to Standard therapy in subjects with Acute Coronary Syndromes - Thrombolysis In Myocardial Infarction 51 BARI 2D Bypass Angioplasty Revascularization Investigation 2 Diabetes BEST Randomized Comparison